Email
Print
Neurodegenerative Disease Market - Forecast(2024 - 2030)
Neurodegenerative Disease Market Overview
The Neurodegenerative Disease Market size
is estimated to reach $49,218 million by 2027. Furthermore, it is poised to
grow at a CAGR of 3.9% over the forecast period of 2022-2027. Neurodegenerative
diseases are a set of brain disorders that cause the structure and function of
neurons in the central nervous system (CNS) and peripheral nervous system (PNS)
to deteriorate over time (PNS). Several drugs are currently available to help
people lessen physical or mental symptoms and improve their quality of life.
Furthermore, researchers are concentrating their efforts on developing
molecular diagnostics, particularly biomarkers and imaging spectroscopy, in
order to detect and diagnose neurodegenerative illnesses at an early stage and
halt their progression. The impact of COVID-19 on the neurodegenerative disease
market is projected to be significant, as the pandemic has disrupted clinical
trial, research and development, and pipeline product workflows, resulting in
relatively modest growth during the pandemic despite a solid late-stage product
pipeline. Despite the pandemic the market is forecasted to gradually recover
and grow in the years of forecast. The companies with higher funding and
revenue are investing more into
R&D with development of unique neurodegenerative disease drugs for the
various neurodegenerative indications while expanding to new geographic
locations through its sales channel expansion. Recently, companies are focusing
on making continuous investment across the business to in order to build and
maintain the pipeline of new drugs for therapeutics. Companies are also
predicted to acquire, grow the foreign market revenue and continue to get
timely regulatory approvals. Rising prevalence of Alzheimer
disease, increasing public awareness, and a strong product pipeline for
neurodegenerative disease treatment are some of the factors driving the drug
Industry forward in the projected period of 2022-2027.
Report Coverage
The
report: “Neurodegenerative Disease Market
Forecast (2022-2027)", by Industry ARC covers an
in-depth analysis of the following segments of the Neurodegenerative
Disease Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021. The growing geriatric population in the US is increasing the prevalence of neurodegenerative diseases as age is the best known risk factor for such diseases. The geriatric population was estimated to be around 65 million in 2020. This is projected to increase by 18 million between 2020 and 2030 and it is estimated that approximately 1 in every 5 Americans will be 65 or more by 2030..
- The surge in neurodegenerative diseases in the US owing to the rising geriatric population is increasing the demand for effective neurodegenerative disease therapies for treating the disease and suppressing symptoms. In addition, it has also resulted in an increase in public R&D expenditure towards drug research, which will further contribute to the market growth. For instance, the Federal Alzheimer's and Dementia Research Funding increased from $2.8 billion in 2019 to $3.2 in 2021.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Neurodegenerative Disease Market Report.
Neurodegenerative Disease Market Segmentation Analysis- By Drug Class
The neurodegenerative disease market based
on drug class can be further segmented into N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Acetylcholinesterase
(AChE) Inhibitors, Dopamine Agonists and Antagonist, Monoamine Oxidase B
(MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor. Immunomodulators
held a dominant market share in the year 2021. Immunomodulators provides very
effective therapy options for a variety of autoimmune and neurodegenerative
illnesses. Furthermore, the growing presence of important companies is likely
to raise patient and physician awareness of the benefits of immunomodulators. As they strive to obtain a competitive
advantage in the market, they are developing novel immunomodulators to treat a
variety of chronic conditions.
However, Vesicular Monoamine Transporter 2
(VMAT2) Inhibitors is estimated to be the fastest-growing, with a CAGR of 13.3%
over the forecast period of 2022-2027. It is owing to increase in number of
patients with bipolar diseases, schizophrenia, and Huntington’s disease and
other neuropsychiatric disorders undergoing long-term medical treatments with
antipsychotic medication. Furthermore, throughout the projected period,
investigational research for the discovery of novel therapies using VMAT2
inhibitors to treat Huntington disease are expected to drive demand.
Neurodegenerative Disease Market Segmentation Analysis- By Indications
The neurodegenerative disease market based
on indications can be further segmented into Parkinson’s
Disease, Huntington Disease, Alzheimer’s Disease, Amyotrophic Lateral
Sclerosis, Multiple Sclerosis, Spinal Muscular Atrophy (SMA) and Others. Multiple Sclerosis held a
dominant market share in the year 2021. Recently, more than 4,00,000 people in
U.S. are suffering from multiple sclerosis which is rising the adoption of
various types of drug class, so the demand for neurodegenerative drugs is
expanding. Apart from this, the breakout of the
COVID-19 pandemic has had a significant impact on the growth of the multiple
sclerosis medications, as it has disrupted the supply chains of numerous
important participants in the industry. For example, Biogen announced that
sales of one of its important medications, TECFIDERA, which is used to treat
multiple sclerosis, fell by 13% in 2020 compared to the previous year such
factors are predicted to have a minor impact on market expansion.
However,
Huntington Disease is estimated to be the fastest-growing, with a CAGR of 13.2%
over the forecast period of 2022-2027. It is owing to various factors such as greater adoption of novel drugs, expanded R&D activity, an
increase in the target population, and supportive regulatory measures are all
driving the Huntington's Disease incidence. Reportedly, more than 20 drugs are
in various phases of clinical trials for the treatment of Huntington's disease.
Neurodegenerative Disease Market Segmentation Analysis- By Geography
The neurodegenerative disease market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 3.1% in the year 2021 as compared to the other counterparts. It is owing to increasing prevalence of neurodegenerative diseases such as Alzheimer diseases, Huntington disease etc. According to the Centers for Disease Control (CDC), Alzheimer's disease is the 6th leading cause of death among US adults. In 2020, it is estimated that more than 5.8 million Americans aged 65 years or older are suffering from Alzheimer’s disease. This is projected to reach 7.7 million by 2030. Meanwhile, according to the Parkinson’s Foundation Prevalence Project, the prevalence of Parkinson’s in the US is predicted to rise from 930,000 in 2020 to 1.2 million by 2030.
Neurodegenerative Disease Market Drivers
Rising prevalence of Alzheimer disease have readily aided the market growth
Alzheimer's disease is a degenerative
neurological disease and the most common form of dementia, characterised by
memory loss, loss of thinking skills, and difficulties with problem-solving and
language. Alzheimer's disease symptoms appear gradually over many years and
eventually grow more severe. According to the World Health Organization (WHO),
in 2021 over 50 million individuals suffer from dementia, a frequent form of
Alzheimer's disease, with 10 million new cases diagnosed each year. The
increased prevalence of these disorders also drives the development of various
medications. Besides, the market is growing as people become more aware of the
drug therapies for Alzheimer's disease around the world. Furthermore, rising
awareness of the different novel treatment alternatives, is also helping to
fuel the rise of Alzheimer's Drugs.
Availability of robust pipeline of drugs for neurodegenerative disease treatment is driving the market growth
Availability of robust pipeline of drugs for
neurodegenerative disorders is forecasted to drive growth of the global
Neurodegenerative Disease Market.
Recently, in 2021, GlaxoSmithKline Plc in
collaboration with Alector Inc. to develop antibody-based treatments for
Parkinson's, Alzheimer's and other similar diseases. This collaboration deals
worth up to $2.2 billion which efforts to build a robust pipeline of drugs.
Neurodegenerative Disease Market Challenges
High cost of treatment are some of the factors impeding the market growth
The
extremely high cost is anticipated to hamper market growth as it limits the access of quality
treatment to the middle and low-income population countries. For instance, in
U.S. the average annual medical cost for the treatment of Multiple Sclerosis
(MS) can reach more than $70,000. This is highly expensive as the country’s
median household income in 2020 was only $67,521.
Neurodegenerative Disease Market Competitive Landscape
Product launches, mergers and acquisitions,
joint ventures, and geographical expansions are key strategies adopted by
players in the Neurodegenerative Disease Market. The top 10- Neurodegenerative
Disease Market companies are-
- Biogen Inc.,
- F. Hoffman La Roche Ltd.,
- Merck KGaA,
- Novartis AG,
- Sanofi,
- Teva Pharmaceuticals Industries Ltd.,
- Orion Corporation,
- H. Lundbeck A/S.,
- Sun Pharmaceutical Industries Ltd.,
- UCB S.A.
Recent Developments
- In May 2021, Biogen Inc. and Envisagenics announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases. As part of the collaboration, Biogen will leverage Envisagenics’ proprietary artificial intelligence (AI)-driven RNA splicing platform, SpliceCore®, to define and understand the regulation of different RNA isoforms in CNS cell types.
- In August 2020, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. This is predicted to drive the SMA indication segment.
- In February 2020, Novartis announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.
Relevant Titles
Alzheimer’s Drugs Market- Forecast
(2022-2027)
Report Code- HCR 0112
Parkinson’s Disease Drugs Market- Forecast
(2022-2027)
Report Code- HCR 17103
For more Lifesciences and Healthcare Market reports, please click here
Table 1: Neurodegenerative Disease Market Overview 2023-2030
Table 2: Neurodegenerative Disease Market Leader Analysis 2023-2030 (US$)
Table 3: Neurodegenerative Disease Market Product Analysis 2023-2030 (US$)
Table 4: Neurodegenerative Disease Market End User Analysis 2023-2030 (US$)
Table 5: Neurodegenerative Disease Market Patent Analysis 2013-2023* (US$)
Table 6: Neurodegenerative Disease Market Financial Analysis 2023-2030 (US$)
Table 7: Neurodegenerative Disease Market Driver Analysis 2023-2030 (US$)
Table 8: Neurodegenerative Disease Market Challenges Analysis 2023-2030 (US$)
Table 9: Neurodegenerative Disease Market Constraint Analysis 2023-2030 (US$)
Table 10: Neurodegenerative Disease Market Supplier Bargaining Power Analysis 2023-2030 (US$)
Table 11: Neurodegenerative Disease Market Buyer Bargaining Power Analysis 2023-2030 (US$)
Table 12: Neurodegenerative Disease Market Threat of Substitutes Analysis 2023-2030 (US$)
Table 13: Neurodegenerative Disease Market Threat of New Entrants Analysis 2023-2030 (US$)
Table 14: Neurodegenerative Disease Market Degree of Competition Analysis 2023-2030 (US$)
Table 15: Neurodegenerative Disease Market Value Chain Analysis 2023-2030 (US$)
Table 16: Neurodegenerative Disease Market Pricing Analysis 2023-2030 (US$)
Table 17: Neurodegenerative Disease Market Opportunities Analysis 2023-2030 (US$)
Table 18: Neurodegenerative Disease Market Product Life Cycle Analysis 2023-2030 (US$)
Table 19: Neurodegenerative Disease Market Supplier Analysis 2023-2030 (US$)
Table 20: Neurodegenerative Disease Market Distributor Analysis 2023-2030 (US$)
Table 21: Neurodegenerative Disease Market Trend Analysis 2023-2030 (US$)
Table 22: Neurodegenerative Disease Market Size 2023 (US$)
Table 23: Neurodegenerative Disease Market Forecast Analysis 2023-2030 (US$)
Table 24: Neurodegenerative Disease Market Sales Forecast Analysis 2023-2030 (Units)
Table 25: Neurodegenerative Disease Market, Revenue & Volume, By Drug class, 2023-2030 ($)
Table 26: Neurodegenerative Disease Market By Drug class, Revenue & Volume, By NMDA, 2023-2030 ($)
Table 27: Neurodegenerative Disease Market By Drug class, Revenue & Volume, By SSRIs, 2023-2030 ($)
Table 28: Neurodegenerative Disease Market By Drug class, Revenue & Volume, By Dopamine Inhibitors, 2023-2030 ($)
Table 29: Neurodegenerative Disease Market, Revenue & Volume, By Indications, 2023-2030 ($)
Table 30: Neurodegenerative Disease Market By Indications, Revenue & Volume, By Parkinson’s & Huntington disease, 2023-2030 ($)
Table 31: Neurodegenerative Disease Market By Indications, Revenue & Volume, By Amyotrophic Lateral Sclerosis, 2023-2030 ($)
Table 32: Neurodegenerative Disease Market By Indications, Revenue & Volume, By Alzheimer’s disease]Chemotherapy, 2023-2030 ($)
Table 33: North America Neurodegenerative Disease Market, Revenue & Volume, By Drug class, 2023-2030 ($)
Table 34: North America Neurodegenerative Disease Market, Revenue & Volume, By Indications, 2023-2030 ($)
Table 35: South america Neurodegenerative Disease Market, Revenue & Volume, By Drug class, 2023-2030 ($)
Table 36: South america Neurodegenerative Disease Market, Revenue & Volume, By Indications, 2023-2030 ($)
Table 37: Europe Neurodegenerative Disease Market, Revenue & Volume, By Drug class, 2023-2030 ($)
Table 38: Europe Neurodegenerative Disease Market, Revenue & Volume, By Indications, 2023-2030 ($)
Table 39: APAC Neurodegenerative Disease Market, Revenue & Volume, By Drug class, 2023-2030 ($)
Table 40: APAC Neurodegenerative Disease Market, Revenue & Volume, By Indications, 2023-2030 ($)
Table 41: Middle East & Africa Neurodegenerative Disease Market, Revenue & Volume, By Drug class, 2023-2030 ($)
Table 42: Middle East & Africa Neurodegenerative Disease Market, Revenue & Volume, By Indications, 2023-2030 ($)
Table 43: Russia Neurodegenerative Disease Market, Revenue & Volume, By Drug class, 2023-2030 ($)
Table 44: Russia Neurodegenerative Disease Market, Revenue & Volume, By Indications, 2023-2030 ($)
Table 45: Israel Neurodegenerative Disease Market, Revenue & Volume, By Drug class, 2023-2030 ($)
Table 46: Israel Neurodegenerative Disease Market, Revenue & Volume, By Indications, 2023-2030 ($)
Table 47: Top Companies 2023 (US$) Neurodegenerative Disease Market, Revenue & Volume
Table 48: Product Launch 2023-2030 Neurodegenerative Disease Market, Revenue & Volume
Table 49: Mergers & Acquistions 2023-2030 Neurodegenerative Disease Market, Revenue & Volume
List of Figures:
Figure 1: Overview of Neurodegenerative Disease Market 2023-2030
Figure 2: Market Share Analysis for Neurodegenerative Disease Market 2023 (US$)
Figure 3: Product Comparison in Neurodegenerative Disease Market 2023-2030 (US$)
Figure 4: End User Profile for Neurodegenerative Disease Market 2023-2030 (US$)
Figure 5: Patent Application and Grant in Neurodegenerative Disease Market 2013-2023* (US$)
Figure 6: Top 5 Companies Financial Analysis in Neurodegenerative Disease Market 2023-2030 (US$)
Figure 7: Market Entry Strategy in Neurodegenerative Disease Market 2023-2030
Figure 8: Ecosystem Analysis in Neurodegenerative Disease Market 2023
Figure 9: Average Selling Price in Neurodegenerative Disease Market 2023-2030
Figure 10: Top Opportunites in Neurodegenerative Disease Market 2023-2030
Figure 11: Market Life Cycle Analysis in Neurodegenerative Disease Market
Figure 12: GlobalBy Drug classNeurodegenerative Disease Market Revenue, 2023-2030 ($)
Figure 13: GlobalBy IndicationsNeurodegenerative Disease Market Revenue, 2023-2030 ($)
Figure 14: Global Neurodegenerative Disease Market - By Geography
Figure 15: Global Neurodegenerative Disease Market Value & Volume, By Geography, 2023-2030 ($)
Figure 16: Global Neurodegenerative Disease Market CAGR, By Geography, 2023-2030 (%)
Figure 17: North America Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 18: US Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 19: US GDP and Population, 2023-2030 ($)
Figure 20: US GDP – Composition of 2023, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2023-2030 ($)
Figure 22: Canada Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 23: Canada GDP and Population, 2023-2030 ($)
Figure 24: Canada GDP – Composition of 2023, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2023-2030 ($)
Figure 26: Mexico Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 27: Mexico GDP and Population, 2023-2030 ($)
Figure 28: Mexico GDP – Composition of 2023, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2023-2030 ($)
Figure 30: South America Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 31: Brazil Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 32: Brazil GDP and Population, 2023-2030 ($)
Figure 33: Brazil GDP – Composition of 2023, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2023-2030 ($)
Figure 35: Venezuela Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 36: Venezuela GDP and Population, 2023-2030 ($)
Figure 37: Venezuela GDP – Composition of 2023, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2023-2030 ($)
Figure 39: Argentina Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 40: Argentina GDP and Population, 2023-2030 ($)
Figure 41: Argentina GDP – Composition of 2023, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2023-2030 ($)
Figure 43: Ecuador Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 44: Ecuador GDP and Population, 2023-2030 ($)
Figure 45: Ecuador GDP – Composition of 2023, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2023-2030 ($)
Figure 47: Peru Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 48: Peru GDP and Population, 2023-2030 ($)
Figure 49: Peru GDP – Composition of 2023, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2023-2030 ($)
Figure 51: Colombia Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 52: Colombia GDP and Population, 2023-2030 ($)
Figure 53: Colombia GDP – Composition of 2023, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2023-2030 ($)
Figure 55: Costa Rica Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 56: Costa Rica GDP and Population, 2023-2030 ($)
Figure 57: Costa Rica GDP – Composition of 2023, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2023-2030 ($)
Figure 59: Europe Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 60: U.K Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 61: U.K GDP and Population, 2023-2030 ($)
Figure 62: U.K GDP – Composition of 2023, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2023-2030 ($)
Figure 64: Germany Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 65: Germany GDP and Population, 2023-2030 ($)
Figure 66: Germany GDP – Composition of 2023, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2023-2030 ($)
Figure 68: Italy Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 69: Italy GDP and Population, 2023-2030 ($)
Figure 70: Italy GDP – Composition of 2023, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2023-2030 ($)
Figure 72: France Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 73: France GDP and Population, 2023-2030 ($)
Figure 74: France GDP – Composition of 2023, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2023-2030 ($)
Figure 76: Netherlands Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 77: Netherlands GDP and Population, 2023-2030 ($)
Figure 78: Netherlands GDP – Composition of 2023, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2023-2030 ($)
Figure 80: Belgium Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 81: Belgium GDP and Population, 2023-2030 ($)
Figure 82: Belgium GDP – Composition of 2023, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2023-2030 ($)
Figure 84: Spain Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 85: Spain GDP and Population, 2023-2030 ($)
Figure 86: Spain GDP – Composition of 2023, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2023-2030 ($)
Figure 88: Denmark Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 89: Denmark GDP and Population, 2023-2030 ($)
Figure 90: Denmark GDP – Composition of 2023, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2023-2030 ($)
Figure 92: APAC Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 93: China Neurodegenerative Disease Market Value & Volume, 2023-2030
Figure 94: China GDP and Population, 2023-2030 ($)
Figure 95: China GDP – Composition of 2023, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2023-2030 ($)Neurodegenerative Disease Market China Export and Import Value & Volume, 2023-2030 ($)
Figure 97: Australia Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 98: Australia GDP and Population, 2023-2030 ($)
Figure 99: Australia GDP – Composition of 2023, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2023-2030 ($)
Figure 101: South Korea Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 102: South Korea GDP and Population, 2023-2030 ($)
Figure 103: South Korea GDP – Composition of 2023, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2023-2030 ($)
Figure 105: India Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 106: India GDP and Population, 2023-2030 ($)
Figure 107: India GDP – Composition of 2023, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2023-2030 ($)
Figure 109: Taiwan Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 110: Taiwan GDP and Population, 2023-2030 ($)
Figure 111: Taiwan GDP – Composition of 2023, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2023-2030 ($)
Figure 113: Malaysia Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 114: Malaysia GDP and Population, 2023-2030 ($)
Figure 115: Malaysia GDP – Composition of 2023, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2023-2030 ($)
Figure 117: Hong Kong Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 118: Hong Kong GDP and Population, 2023-2030 ($)
Figure 119: Hong Kong GDP – Composition of 2023, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2023-2030 ($)
Figure 121: Middle East & Africa Neurodegenerative Disease Market Middle East & Africa 3D Printing Market Value & Volume, 2023-2030 ($)
Figure 122: Russia Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 123: Russia GDP and Population, 2023-2030 ($)
Figure 124: Russia GDP – Composition of 2023, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2023-2030 ($)
Figure 126: Israel Neurodegenerative Disease Market Value & Volume, 2023-2030 ($)
Figure 127: Israel GDP and Population, 2023-2030 ($)
Figure 128: Israel GDP – Composition of 2023, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2023-2030 ($)
Figure 130: Entropy Share, By Strategies, 2023-2030* (%)Neurodegenerative Disease Market
Figure 131: Developments, 2023-2030*Neurodegenerative Disease Market
Figure 132: Company 1 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 133: Company 1 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 134: Company 1 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 135: Company 2 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 136: Company 2 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 137: Company 2 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 138: Company 3 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 139: Company 3 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 140: Company 3 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 141: Company 4 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 142: Company 4 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 143: Company 4 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 144: Company 5 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 145: Company 5 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 146: Company 5 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 147: Company 6 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 148: Company 6 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 149: Company 6 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 150: Company 7 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 151: Company 7 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 152: Company 7 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 153: Company 8 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 154: Company 8 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 155: Company 8 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 156: Company 9 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 157: Company 9 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 158: Company 9 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 159: Company 10 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 160: Company 10 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 161: Company 10 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 162: Company 11 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 163: Company 11 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 164: Company 11 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 165: Company 12 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 166: Company 12 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 167: Company 12 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 168: Company 13 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 169: Company 13 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 170: Company 13 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 171: Company 14 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 172: Company 14 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 173: Company 14 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)
Figure 174: Company 15 Neurodegenerative Disease Market Net Revenue, By Years, 2023-2030* ($)
Figure 175: Company 15 Neurodegenerative Disease Market Net Revenue Share, By Business segments, 2023 (%)
Figure 176: Company 15 Neurodegenerative Disease Market Net Sales Share, By Geography, 2023 (%)